- Home
- RNA vs PLXS Comparison
RNA vs PLXS Comparison
Compare RNA & PLXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNA | PLXS |
|---|---|---|
| Founded | 2012 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.0B |
| IPO Year | 2020 | 1986 |
Fundamental Metrics
Financial Performance| Metric | RNA | PLXS |
|---|---|---|
| Price | $71.76 | $149.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 4 |
| Target Price | $69.26 | ★ $157.50 |
| AVG Volume (30 Days) | ★ 2.9M | 164.5K |
| Earning Date | 11-10-2025 | 01-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.11 |
| EPS | N/A | ★ 6.26 |
| Revenue | $20,868,000.00 | ★ $4,032,966,000.00 |
| Revenue This Year | $64.11 | $10.99 |
| Revenue Next Year | $37.25 | $7.02 |
| P/E Ratio | ★ N/A | $24.02 |
| Revenue Growth | ★ 106.27 | 1.82 |
| 52 Week Low | $21.51 | $103.43 |
| 52 Week High | $71.79 | $172.89 |
Technical Indicators
Market Signals| Indicator | RNA | PLXS |
|---|---|---|
| Relative Strength Index (RSI) | 77.56 | 60.30 |
| Support Level | $71.42 | $141.26 |
| Resistance Level | $71.76 | $151.86 |
| Average True Range (ATR) | 0.41 | 5.09 |
| MACD | -0.73 | 1.22 |
| Stochastic Oscillator | 88.32 | 88.05 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About PLXS Plexus Corp.
Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.